State of Alaska Department of Revenue trimmed its position in Glaukos Co. (NYSE:GKOS) by 16.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 34,990 shares of the medical instruments supplier’s stock after selling 6,800 shares during the period. State of Alaska Department of Revenue owned 0.08% of Glaukos worth $2,633,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the stock. US Bancorp DE grew its holdings in shares of Glaukos by 137.9% during the third quarter. US Bancorp DE now owns 590 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 342 shares during the last quarter. Glenmede Trust Co. NA increased its position in Glaukos by 240.6% in the second quarter. Glenmede Trust Co. NA now owns 831 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 587 shares during the period. Strs Ohio increased its position in Glaukos by 900.0% in the third quarter. Strs Ohio now owns 1,000 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 900 shares during the period. Marshall Wace North America L.P. acquired a new stake in Glaukos in the first quarter worth $55,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Glaukos in the second quarter worth $104,000.
NYSE:GKOS opened at $84.18 on Thursday. The business’s 50-day moving average price is $72.05 and its 200 day moving average price is $49.50. The firm has a market cap of $3.78 billion, a P/E ratio of -51.02 and a beta of 1.87. Glaukos Co. has a 52-week low of $23.31 and a 52-week high of $84.47. The company has a quick ratio of 9.31, a current ratio of 9.73 and a debt-to-equity ratio of 0.37.
In related news, Director William J. Phd Link sold 50,000 shares of the stock in a transaction on Tuesday, December 1st. The stock was sold at an average price of $67.97, for a total value of $3,398,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.20% of the company’s stock.
GKOS has been the topic of several analyst reports. Wells Fargo & Company raised Glaukos from an “underweight” rating to an “equal weight” rating and set a $68.00 target price on the stock in a research report on Tuesday, November 17th. Piper Sandler raised their price target on Glaukos from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Friday, November 6th. BidaskClub lowered Glaukos from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 30th. JPMorgan Chase & Co. lowered Glaukos from a “neutral” rating to an “underweight” rating and set a $50.00 price target on the stock. in a report on Thursday, October 8th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised Glaukos from a “sell” rating to a “neutral” rating and raised their price target for the company from $50.00 to $72.00 in a report on Wednesday, December 16th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $57.40.
Glaukos Company Profile
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Story: Dividend Achievers
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.